# A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies

> **NCT04556266** · PHASE1 · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Leukemia
- Lymphoma
- Lymphoma, B-Cell

## Interventions

- **BIOLOGICAL:** CAR T-Cell Infusion

## Key facts

- **NCT ID:** NCT04556266
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-01
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients were enrolled to this study since being open to enrollment. Due to changes in available therapies, there aren't enough people who will be eligible for the study. Therefore, the study was closed.
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04556266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04556266, "A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04556266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*